A proSpective randomized Study comparing the effects of Empagliflozin versus sitagliptin on cardiac fat and function in patients with Type 2 diabetes (ASSET study)
Latest Information Update: 06 Sep 2022
Price :
$35 *
At a glance
- Drugs Empagliflozin (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ASSET
- 05 Sep 2022 Status changed from recruiting to completed.
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 03 Mar 2018 Status changed from not yet recruiting to recruiting.